Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection

Read full release

Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results

Read full release

Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients

Read full release

Oxford University and Vaccitech welcome UK regulatory emergency use authorisation of coronavirus vaccine

Read full release

Clinical trial data shows Oxford University’s COVID-19 vaccine produces strong immune response

Read full release